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Abstract
Background: Lung cancer remains the leading cause of cancer-related mortality despite continuous efforts to find
effective treatments. Data from the American Cancer Society indicate that while the overall incidence of lung
cancer is declining, it continues to rise in women. Stem cell-based therapy has been an emerging strategy to treat
various diseases. The purpose of this paper is to determine the efficacy of an intrinsic anti-cancer effect of rat
umbilical cord matrix stem cells (UCMSCs) on lung cancer.
Methods: A mouse syngeneic lung carcinoma model was used to test the basic ability of UCMSCs to control the
growth of lung cancer. Lung tumors were experimentally induced by tail vein administration of Lewis lung
carcinoma (LLC) cells derived from the lung of C57BL/6 mouse. Rat UCMSCs were then administered intratracheally
five days later or intravenously on days 5 and 7. The tumor burdens were determined by measuring lung weight
three weeks after the treatment.
Results: Co-culture of rat UCMSCs with LLC significantly attenuated the proliferation of LLC cells as monitored by
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), a tetrazole cell proliferation assay, thymidine
uptake, and direct cell counts. In vitro colony assays with rat UCMSCs as feeder layers markedly reduced LLC colony
size and number. Co-culture of rat UCMSCs with LLCs causes G0/G1 arrest of cancer cells. This is evident in the
decrease of cyclin A and CDK2 expression. The in vivo studies showed that rat UCMSC treatment significantly
decreased tumor weight and the total tumor mass. Histological study revealed that intratracheally or systemically
administered rat UCMSCs homed to tumor areas and survived for at least 3 weeks without any evidence of
differentiation or adverse effects.
Conclusions: These results indicate that rat UCMSCs alone remarkably attenuate the growth of lung carcinoma
cells in vitro and in a mouse syngeneic lung carcinoma graft model and could be used for targeted cytotherapy
for lung cancer.
Background
Despite rapid advances in diagnostic and operative techni-
ques, lung cancer remains one of the most difficult human
malignancies to treat. The American Cancer Society esti-
mates that 214,440 persons in the United States developed
lung cancer in 2009, with 159,390 deaths [1]. Lung cancer-
dependent deaths constituted 30% (men) and 26%
(women) of the estimated total cancer-related deaths in
2009 [1]. Data from the American Cancer Society indicate
that while the overall incidence of lung cancer is declining,
it continues to rise in women [1]. The possible treatments
for lung cancer include surgical resection, chemotherapy,
radiotherapy, and/or combination therapy. Recently, mul-
tiple new chemotherapeutic agents have been developed
and some are in clinical trials [2,3]. Although some of
these have produced promising results, their therapeutic
spectrum is narrow.
Genetically engineered mesenchymal stem cells
derived from the umbilical cord matrix have great
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any medium, provided the original work is properly cited.potential for therapeutic application in various diseases
including cancer. However, a major advantage would be
realized if tumor-trafficking stem cells that have not been
genetically modified exhibit an inherent anti-tumor effect,
thus circumventing the necessity of the expression of exo-
genous genes by the cells. It is well known that stem cells
have inherent tumoritropic migratory properties [4]. Sig-
nals that mediate this effect appear to be similar or identi-
cal to those that mediate recruitment of stromal or
defensive cells in tumors [5-7]. There are also a number of
reports showing that genetically engineered stem cells effi-
ciently deliver therapeutic proteins to cancer and other
sites of inflammation [4,6,8-12]. Stem cells we have iso-
lated from the Wharton’s jelly of umbilical cord, termed
‘umbilical cord matrix stem cells’ (UCMSCs), also exhibit
inherent tumoritropic migratory properties [8].
UCMSCs may be more useful for cancer therapy than
other adult stem cells, since they are easy to prepare in
relatively large quantities from umbilical cords after
delivery and pose no ethical issues. They are potentially
quite applicable to human patients without a complete
genetic match, since they are unlikely to induce an
acute immune response [13,14]. The versatility and
availability of umbilical cord stem cells makes them a
potent resource for transplant therapies for various dis-
eases, including cancer. When these cells are engineered
to secrete a cytokine, interferon beta (IFN-b), and are
administered intravenously, they can attenuate meta-
static breast cancer in a SCID mouse model [8].
Recently we found that rat UCMSCs completely abol-
ished the growth of Mat B III cancer cells in vitro and
in vivo [15]. Furthermore, un-engineered human
UCMSCs have been shown to attenuate human breast
cancer xenografts in a SCID mouse model [16]. Accord-
ingly, the primary objective of the present study was to
explore the therapeutic potential of rat UCMSCs against
lung cancer using an LLC tumor model in syngeneic
immunocompetent mice. This study surprisingly indi-
cated that, even in trans-species transplantation, rat
UCMSCs have exhibited a profound anti-tumor effect
on lung carcinoma without any significant rejection of
transplanted rat UCMSCs.
Methods
Cell culture
Rat UCMSCs were prepared from E19 pregnant rats and
isolated using the method described previously [15].
Cells were maintained in defined medium, containing a
mixture of 56% low glucose Dulbecco’s Modified Eagle
Medium (DMEM, Invitrogen, CA); 37% MCDB 201
(Sigma; St. Louis, MO); 2% fetal bovine serum (FBS,
Atlanta Biologicals Inc, GA); 1x insulin-transferrin-sele-
nium-X (ITS-X, Invitrogen); 1x ALBUMax1 (Invitrogen);
1x penicillin/streptomycin (Pen/Strep, Invitrogen);
10 nM dexamethasone (Sigma); 100 μMa s c o r b i ca c i d
2-phosphate (Sigma); 10 ng/ml epidermal growth factor
( E G F ,R & Ds y s t e m s ,M i n n e a p o l i s ,M N ) ;a n d1 0n g / m l
platelet derived growth factor-BB (PDGF-BB, R&D sys-
tems). Cells were maintained at 37°C in a humidified
atmosphere containing 5% CO2.
The LLC cell line was maintained in DMEM (Invitro-
gen) medium supplemented with 10% FBS and 1x Pen/
Strep (Invitrogen). Cells were cultured at 37°C in a
humidified atmosphere containing 5% CO2.
Cell proliferation assay
The MTT assay was performed to study the effect of rat
UCMSCs on LLC cell proliferation. In brief, different
ratios of rat UCMSCs and LLCs (UCMSCs:LLCs = 1:10,
1:6, and 1:3) in DMEM with 10% FBS were seeded in 96
well plates; cells were allowed to grow for 72 hrs. MTT
solution (20 μlo f5m g / m l )w a sa d d e d4h r sb e f o r e
completing 72 hrs of incubation. Formazan crystals
formed were dissolved by adding 100 μl solublization
buffer (10% SDS containing 0.01N HCl) and incubated
overnight at 37°C. The following day, color developed
was measured at 550 nm and background absorbance
was measured at 630 nm using the Molecular Devices
Spectramax 190 plate reader (Global Medical Instru-
mentation, Inc. Ramsey, MN).
[
3H] thymidine uptake assay
To evaluate cell proliferation from a different angle, a
[
3H] thymidine uptake assay was carried out. In brief,
rat UCMSCs (1 × 10
3 or 2 × 10
3/well) were mixed with
6×1 0
3 LLC cells/well, directly plated in 24-well culture
plates, and cultured in a CO2 incubator for 72 hrs.
Radioactivity incorporated into the cells was analyzed
using our published protocol[15].
Transwell cell culture study
Direct cell counts via hemocytometer were performed to
study the effect of rat UCMSCs on LLC cell growth in
culture plates with cell culture inserts (BD Biosciences,
San Jose, CA). In brief, LLC cells were seeded in normal
growth medium at 1 × 10
5 cells/well in 6-well plates.
After allowing the cancer cells to adhere for 1 hr, 1.67 ×
10
4 and 3.33 × 10
4 rat UCMSCs were seeded on the cell
culture inserts (3.0 μm pore size). The insert pore size of
3 μm is small enough to prevent cells migrating from the
inserts to the culture dishes, since UCMSCs do not pene-
trate this size pores in the insert. After 72 hrs co-culture,
c e l l sg r o w ni nt h eb o t t o mc u l ture dish were collected by
trypsinization and counted using a hemocytometer.
Colony formation study
Various numbers of rat UCMSCs (8.33 × 10
2 and 1.67 ×
10
3 cells/well) were grown in a 12 well tissue culture
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que agar, Cambrex Bio Science Rockland, Inc. Rockland,
ME) in DMEM with 10% FBS was poured into the dish
(bottom layer). After the bottom agar layer solidified,
LLC cells (5 × 10
3 cells) were suspended in 0.5 ml of
DMEM containing 10% FBS and 0.5% agar and plated
on top of the bottom agar layer. The cells were incu-
b a t e da t3 7 ° Cw i t h5 %C O 2 for growth of colonies. On
day 16, colony growth was evaluated by an automated
phase contrast microscope equipped with Micro Suite
Analysis Suite (Olympus CKX41, Center Valley, PA).
Colonies with an area greater than 50000 μm
2 were
counted using Micro Suite Analysis Suite software.
Cell cycle analysis
To analyze the effect of rat UCMSC co-culture on LLC
cells, cell cycle analysis was carried out using propidium
iodide staining. In brief, rat UCMSCs and LLC cells
were co-cultured in 6 well Transwell culture dishes as
described in the Transwell cell culture study. At the end
of incubation LLC cells in the bottom chamber were
collected and analyzed for cell cycle using our standard
protocol [16].
Western blot analysis
Total cellular protein was prepared using lysis buffer
(1% TritonX-100, 0.1% SDS, 0.25M sucrose, 1 mM
EDTA, 30 mM Tris-HCl (pH 8.0)) supplemented with
protease inhibitor cocktail (Boehringer Mannheim,
Indianapolis, IN). Protein samples were separated by a
10% SDS-PAGE gel, electroblotted onto nitrocellulose
membrane (GE Healthcare, Uppsala, Sweden) and
blocked with 4% nonfat dry milk in 0.1% Tween20 in
phosphate buffered saline (PBST) for 1 hr at room tem-
perature. The membranes were washed and incubated
with antibodies against cyclin A (1:100, Abcam,
Cambridge, MA), cyclin E (1:100, Abcam), and CDK2
(1:100, Santa Cruz Biotechnology, Santa Cruz, CA) with
4% nonfat dry milk in PBST for 1 hr at room tempera-
ture and then with a horseradish peroxidase-conjugated
anti-rabbit IgG secondary antibody (GE Healthcare).
The protein expression signal was detected with Pierce
ECL Western Blotting substrate (Pierce, Rockford, IL).
GAPDH was used as the loading control of sample by
reprobing with an anti-GAPDH antibody (1:4000, Santa
Cruz Biotechnology).
Animals
Wild-type female C57BL/6 mice were obtained from
the Jackson Laboratory (Bar Harbor, ME). All mice
were housed in an AAALAC-accredited clean facility
and held for 10 days to acclimatize. All animal proce-
dures received prior approval from the Kansas State
University Institutional Animal Care and Use
Committee (protocol # 2681) and were performed in
adherence with all applicable international, federal,
state, and local guidelines.
Systemic transplantation of LLC in lung and UCMSC
treatment
To study the effect of rat UCMSCs on the growth of
lung cancer grafts, a syngeneic LLC tumor model was
used. In brief, each mouse was injected via the tail vein
with 1.5 × 10
6 LLC cells (for Experimental design I) or
2×1 0
6 cells (for Experimental design II) suspended in
200 μl of PBS. On day 5 all mice were randomized into
two treatment groups: a PBS control group and a rat
UCMSC treatment group. To evaluate the trafficking of
transplanted UCMSCs, cells were labeled with 10 μg/ml
of SP-DiI fluorescent dye (Molecular Probes, CA) for 16
hrs incubation in a 5% CO2 incubator. After removing
excess dye by washing the cells with PBS, cells were
incubated with dye-free medium for another 4 hrs.
These cells were dispersed by trypsinization and mixed
with unlabeled UCMSCs so that 20% of the UCMSCs
were labeled with SP-DiI. Although a preliminary cell
culture study indicated that SP-DiI does not alter viabi-
lity of UCMSCs, only 20% of transplanted cells were
labeled in order to minimize any potential adverse
effects of the dye. Two experimental designs were used
for UCMSC injections.
Experimental design I
five days after LLC cell injection, these mice were
injected intratracheally using a 27 gauge needle with
either 35 μlP B S( n=8 )o r3 5μl rat UCMSCs suspen-
sion (3.5 × 10
5 cells in PBS, n = 9). The cell suspension
in the syringe was released at approximately 5 mm
above the dividing point of the bronchi. Our preliminary
evaluations have shown that this injection method
evenly distributes injected cells into the right and left
lobes of the lung. Experimental design II:O nd a y5
and day 7 after LLC injection, these mice were systemi-
cally injected using a 28 gauge needle with either 200 μl
PBS (n = 8) or 200 μlU C M S C ss u s p e n s i o n( 1×1 0
6
cells in PBS, n = 8) through the tail vein (IV).
A l lm i c ew e r ek e p ti nt h e i rc a g e sa n dt h e i rp h y s i c a l
condition was monitored until sacrifice on day 21 after
LLC transplantation. Lungs of mice were collected
immediately after sacrifice without inflation treatment,
fixed in 10% formalin in saline, and used for histochem-
ical analysis.
Histopathology
Lung tissue fixed in 10% formalin in saline was
embedded in paraffin, serially sectioned at 4 μm, and
stained with hematoxyline and eosin (H&E) for micro-
scopic examination of morphology of tumors. Unstained
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for nuclei and observed under epifluorescence micro-
scopy for tracking the rat UCMSCs.
Detection of apoptosis in tumors
To determine apoptosis in the tumors, the DeadEndTM
colorimetric TUNEL system (Promega, Madison, WI)
was used according to the manufacturer’sp r o t o c o lw i t h
a slight modification. The sections were counterstained
with methyl green. To determine the apoptotic index,
10 nodules were selected randomly by light microscopy
and the area of TUNEL positive cells in each nodule
was calculated using the NIH Image J analysis software.
The index was assessed as the percentage of TUNEL-
positive area in the tumor. The fold change was calcu-
lated by dividing TUNEL-positive area in rat UCMSC
treated tumors by those in untreated tumors.
Statistical analysis
All values are expressed as means ± SE. For all in vitro
and in vivo experiments, statistical significance was
assessed by Tukey-Kramer Pairwise Comparisons test.
All experiments were conducted at least twice with mul-
tiple sample determinations. Actual number of experi-
ments repeated and sample numbers/experiments are
described in the figure legends. Since all experiments
were very closely reproduced, raw values were used for
the statistical analysis. Data from replicate experiments
as well as replicates within experiments were combined
with no for experiment. A value of P < 0.05 was consid-
ered significant.
Results
Rat UCMSCs inhibit anchorage-dependent and
-independent growth of LLC cells
The effect of un-engineered rat UCMSCs on anchorage-
dependent growth of LLC cells was evaluated by both
direct and indirect co-culture. As shown in Figure 1,
direct co-culture of rat UCMSCs with LLC cells (ratio,
1:6 or 1:3) markedly decreased the total LLC cell number
as measured by MTT assay. DNA synthesis as deter-
mined by thymidine uptake assay was in good agreement
with the MTT assay result (Figure 2), although significant
growth inhibition of LLC cells by rat UCMSCs was
observed with a smaller proportion of UCMSCs in the
MTT assay (UCMSC:LLC = 1:6) than in the thymidine
uptake assay (UCMSC:LLC = 1:3). In addition to these
studies in which both cell types directly contacted each
other, an indirect co-culture study was carried out using
a Transwell culture system in which rat UCMSCs were
cultured in inserts and LLC cells were cultured in the
bottom of the well. The effect of this indirect co-culture
was assessed by counting the LLC cells after 72 hrs co-
culture. The findings of this experiment (Figure 3) also
corroborate with the results from the MTT and thymi-
dine uptake assays. Un-engineered rat UCMSCs dose-
dependently attenuated the total number of LLC cells.
This Transwell experiment suggests that rat UCMSC-
dependent cell growth attenuation may be mediated
through a diffusible molecule or molecules produced by
rat UCMSCs. Another Transwell cell culture in which
LLC cells (1 × 10
5 cells) were cultured in the inserts and
rat UCMSCs (1.7 × 10
3) were cultured in the bottom of
the wells revealed that LLC cells do not alter the growth
of rat UCMSCs (data not shown).
Since anchorage-independent growth is a hallmark of
tumorigenesis, a soft agar assay was carried out to evalu-
ate the effect of rat UCMSCs on the growth of LLC cell
Figure 1 Direct co-culture of a small number of rat UCMSCs
significantly attenuated the growth of LLC cells. Rat UCMSCs
(300, 500 and 1000 cells/well) were co-cultured with 3 × 10
3 LLC
(rat UCMSCs: LLC ratio, 1:10, 1:6 and 1:3). After three days of co-
culture, the MTT assay was carried out. Panel A shows the
morphology of LLC alone or LLC co-cultured with rat UCMSCs for
72 hrs. Scale bars in the pictures indicate 1000 μm. Panel B shows
the summarized results from the MTT assay. The experiment was
performed twice with 6 determinations at each point.
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to mimic in vivo xenograft models. The results showed
that LLC cell colony size and number in soft agar were
significantly attenuated when rat UCMSCs were cul-
tured in the bottom of the culture dish (Figure 4). Since
LLC cells were separated from rat UCMSCs by a solid
agar layer (approximately 1 mm thickness), and the two
cell types physically do not contact each other, the col-
ony assay results also suggest that rat UCMSC-
dependent growth attenuation was mediated through
molecules produced by rat UCMSCs which diffused to
LLC cells.
Rat UCMSCs induced G0/G1 cell cycle arrest
The effect of rat UCMSCs on the cell cycle of LLC cells
was evaluated by flow cytometry after the LLC cells
were co-cultured with rat UCMSCs in Transwell culture
dishes. The result shows that rat UCMSCs caused G0/
G1 arrest of LLC cells, thus increasing the G0/G1 popu-
lation and decreasing the S phase population of LLC
cells (Figure 5A). As shown in Figure 5B, the G0/G1
phase cell populations (%) in LLC alone, LLC:UCMSCs
(6:1), and LLC:UCMSCs (3:1) were 39.02 ± 0.06, 39.89 ±
0.11, and 45.84 ±0.81, respectively; S phase populations
(%, same order as above) were 49.35 ± 0.24, 49.69 ±
0.25, and 41.33 ±0.63, respectively. Furthermore, cyclins
Figure 2 [
3H]-thymidine-uptake into LLC cells was significantly
attenuated by co-culture with a small number of rat UCMSCs.
This experiment suggests that direct co-culture of a small number
of rat UCMSCs significantly attenuates division of LLC cells. Rat
UCMSCs (1 × 10
3 or 2 × 10
3/well) were co-cultured with LLC cells
(6 × 10
3) in a 24-well culture plate. The [
3H] thymidine-uptake was
evaluated 72 hrs after the co-culture, as described in the Materials
and Methods section. The experiment was performed twice with
quadruplicate determinations.
Figure 3 Rat UCMSCs significantly attenuated the growth of
LLC cells in a Transwell co-culture. This experiment suggests that
indirect co-culture of a small number of rat UCMSCs significantly
attenuates the growth of LLC cells. Panel A shows the morphology
of LLC alone or LLC indirectly co-cultured with rat UCMSCs for 72
hrs. Panel B shows the summarized results from direct cell counts
using a hemocytometer. The experiment was performed twice with
triplicate determinations.
Figure 4 Rat UCMSCs significantly attenuated colony growth of
LLC cells. Panel A shows the morphology of colonies of LLC alone
or LLC co-cultured with rat UCMSCs in soft agar after 16 days. Panel
B shows the summarized results from the colony assay. The
experiment was performed twice with triplicate determinations.
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blot analysis. As shown in Figure 6, co-culture with rat
UCMSCs significantly attenuated protein expression
levels of cyclin A and CDK2, but not cyclin E. These
results also indicate cell cycle arrest in G0/G1 phase.
Un-engineered rat UCMSCs significantly attenuate growth
of LLC grafts in syngeneic mice
We tested the growth attenuation ability of un-
engineered naïve rat UCMSCs on the lung LLC tumors
by local (intratracheal) and systemic (IV) administration.
Results indicate that a single intratracheal administra-
tion of rat UCMSCs 5 days after LLC transplantation
almost completely inhibited tumor growth as measured
by tumor weight (Figure 7A). The IV administration of
rat UCMSCs also significantly attenuated tumor growth
despite the fact that tumor growth was more prominent
due to a larger number of the LLC cells transplanted
(2 million cells/mouse) (Figure 7B). Histological analysis
revealed that lungs of PBS injected mice were occupied
by large amounts of cancer tissue, whereas rat UCMSC-
treated groups contained almost negligible (intratracheal
injection group) or very small amounts of tumor mass
(systemic injection group). Fluorescence microscopic
observation of serial sections used for H&E staining
shows the engraftment of rat UCMSCs in close
proximity to or within tumor tissues of tumor bearing
mice that received SP-DiI labeled rat UCMSCs either
intratracheally or systemically (Figure 8). However, SP-
DiI labeled rat UCMSCs were not detected in normal
areas of the lung.
Rat UCMSC treatment markedly increased apoptosis in
tumor tissues
To evaluate the effect of the rat UCMSCs on the apop-
totic activities of tumor cells in vivo, the percentage of
TUNEL-positive cell area in the tumors was determined.
The percentage of TUNEL-positive cell area was two
times higher in rat UCMSC treated tumors than in PBS
treated control tumors (Figure 9). These results indi-
cated that treatment with un-engineered rat UCMSCs
increases apoptosis significantly.
Discussion
The present study shows for the first time that naïve rat
UCMSCs have the potential to attenuate rapidly grow-
ing murine lung carcinoma cells in a syngeneic mouse
model. This effect was observ e di nm o s tt u m o r - b e a r i n g
mice transplanted either locally or systemically with rat
Figure 5 Indirect co-culture of a small number of rat UCMSCs
with LLC cells in a Transwell cell culture caused G0/G1 arrest
in LLC cells. In the co-culture study, 1.67 × 10
4 or 3.33 × 10
4 rat
UCMSCs were placed in the culture plate inserts and co-cultured
with 1 × 10
5 LLC cells in the bottom of the culture plates. After two
to three days co-culture, LLC cells were collected from the bottom
chamber by trypsinization and subjected to flow cytometry as
described in Materials and Methods. Panel A represents the flow
cytometry result and panel B represents the histogram pattern of
different phases of the cell cycle. The experiment was performed
twice with triplicate determinations.
Figure 6 Rat UCMSCs significantly attenuated protein
expression of both cyclin A (Panels A and B) and CDK2 (Panels
A and C), but not cyclin E (Panel A), in co-cultured LLC cells.
This experiment suggests that indirect co-culture of a small number
of rat UCMSCs caused G0/G1 arrest in LLC cells. Samples were
prepared as described in the Figure 5 legend and in Materials and
Methods, and subjected to Western blot analysis. Sample
preparation and Western blot analysis were performed three times
with duplicate determinations. The pictures (Panel A) represent
typical blotting results. P values were calculated as compared to the
level of control.
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important new findings: 1. in co-culture, a relatively
small number of rat UCMSCs significantly attenuated
proliferation of LLC cells; 2. in vitro three dimensional
LLC colony formation is markedly attenuated when rat
UCMSCs are present as a monolayer in the bottom of
the culture; 3) rat UCMSCs caused G0/G1 arrest in
L L C s ,a n dt h i sm a yb eap o s s i b l em e c h a n i s mo fg r o w t h
attenuation; 4) either local or systemic rat UCMSC ther-
apy significantly decreased the lung tumor burden; 5)
rat UCMSCs administered intratracheally or IV ‘home’
into or near the lung tumors
Attenuation of tumor cell growth by rat UCMSCs
appears to have both contact-independent and -depen-
dent components. Interestingly, Khakoo et al.s h o w e d
that bone marrow mesenchymal stem cells could only
mediate their effect on Kaposi sarcoma by contact with
the tumor cells in vitro [17]. Here we showed that in
co-culture assays (Figures. 1 and 2); rat UCMSCs co-
cultured with LLC cells significantly attenuate LLC cell
proliferation. Since the number of rat UCMSCs was sig-
nificantly smaller than LLCs (1:6 or 1:3), this rat
UCMSC-dependent effect is not strictly contact-
mediated; it is likely that some factor(s) independent of
cell-to-cell contact is involved. In the Transwell co-
culture study and soft agar colony assay, in which LLC
cells were not in direct contact with rat UCMSCs (Fig-
ures. 3 and 4), the LLC growth inhibition by rat
UCMSCs implies involvement of a diffusible factor or
factors secreted by the stem cells. This implication is in
good agreement with previous studies from our labora-
tory in which rat UCMSCs attenuated growth of rat
mammary carcinoma cells, apparently through diffusible
molecules [15]. This factor may be associated with the
regulation of the cell cycle, since the present study
clearly indicated that rat UCMSCs induced G0/G1 arrest
in LLC cells when they were co-cultured in a Transwell
culture system (Figure 5), in which the two cell types do
not have direct contact. Furthermore, the anti-tumor
effect shown here may also be associated with pro-apop-
totic factors produced by naïve rat UCMSCs (Figures. 6
and 9). Based on the present study, cell cycle regulation-
and/or apoptosis-associated genes may be good candi-
dates. However, an involvement of other mechanisms,
such as a stimulation of the host immune system, may
also be a part of tumor growth attenuation in vivo.
The homing ability of stem cells has previously been
exploited for drug delivery and targeted gene delivery
[5,6,8-10,12,18]. The homing of stem cells to tumors
and other areas of inflammation is well established
[5-8,19]. The homing ability of stem cells appears to be
mediated by chemokines secreted by the tumors or their
associated stroma [20-22]. Potential chemokines could
include growth factors such as platelet derived growth
factor (PDGF) family members and epidermal growth
factor (EGF) [23] in addition to classical chemo-
attractants such as CXCR4 and its ligand, SDF-1. In the
present study, SP-DiI-loaded rat UCMSCs were detected
either within the tumors or adjacent to the tumors (Fig-
u r e8 ) .P o t e n t i a lr e a s o n sw h yo n l yaf e wd y el o a d e d
UCSMCs were detected in lung tumor sites follow: 1)
lung tissue was fixed with 10% formalin, and formalin is
known to have a fluorescence quenching effect; 2) only
20% of UCMSCs were labeled by SD-DiI; and 3) the
Figure 7 Administration of rat UCMSCs significantly attenuated
the growth of LLC tumors in a syngeneic mouse model. Panel
A shows that lung weight in mice transplanted with one million
LLC cells declines almost to non-cancerous control levels after a
single intratracheal administration of rat UCMSCs (0.35 million cells).
Panel B shows that systemic transplantation of rat UCMSCs (one
million cells twice) also significantly decreased the weight of the
LLC-bearing lungs despite a marked increase of tumor burden due
to a larger number of LLC cells transplanted (two million cells). In
both experiments, eight mice per group were used except for the
rat UCMSCs intratracheally administered group, which consisted of
nine mice.
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a4μm section are relatively low even if a large number
of cells were localized in the entire tumor area. Thus,
detection of even a small number of SP-DiI-loaded rat
UCMSCs in or adjacent to the tumors may imply that
rat UCMSCs were attracted to the chemokines pro-
duced by tumor tissues and homed to the tumor tissues.
The ability of naïve UCMSCs to eliminate lung adeno-
carcinomas is a distinct advantage, since any manipula-
tion causing the cells to express an exogenous gene
could alter them in some way that would potentially
make them less safe as transplantable cells. However,
since rat UCMSCs are not directly applicable to human
therapy, key mechanism(s) by which rat UCMSCs exhi-
bit their powerful anti-tumor effect should be identified
first. This mechanism may be applied to human
UCMSCs for future human application. Therefore, it
will be worthwhile to identify which genes or gene pro-
ducts make rat UCMSCs so powerful for attenuation of
lung cancer growth. If human UCMSCs are as potent as
rat UCMSCs, human UCMSCs will potentially be
utilized for human cancer therapy. If human UCMSCs
are not as potent as rat UCMSCs, their cytotoxicity to
cancer cells may be enhanced by manipulation of their
gene expression based on the study of rat UCMSC-
dependent cytotoxicity against lung cancer.
I nt h i ss t u d yw eh a v eu s e dr a to r i g i nU C M S C sf o ra
mouse cancer model and they have shown a very strong
effect. Whether the rat UCMSC-dependent anti-tumorige-
netic effect is partially due to the xenotransplantation is
unclear. However, since rat UCMSCs were extremely
potent in cell growth attenuation in simple in vitro cell
culture studies where no immune cells or immunoglobulin
were involved, it is likely that their in vivo effect is also
independent of nonspecific immune surveillance induced
by xenotransplantation. In support of this, histopathologi-
cal analysis did not show lymphocyte infiltration in tumor
tissues (data not shown). In addition, our previous finding
that human UCMSCs are poorly immunogenic [14] also
indirectly supports the above speculation.
Naïve UCMSCs have many potential advantages for
cytotherapy. Among many tissue-originated multipotent
Figure 8 SP-DiI labeled rat UCMSCs administered intratracheally were detected near the tumors. This experiment suggests that
intratracheally administered rat UCMSCs home at adjacent to the lung tumor area. Serial sections from paraffin-embedded lung were used for
the detection of rat UCMSCs labeled with SP-DiI fluorescent dye either with SP-DiI fluorescence alone (B-i) or with both DAPI nuclear staining
and SP-DiI fluorescence (B-ii). Tumor morphology was observed after H&E staining (A, PBS-treated tumors, arrows indicate tumors, and B-iii, rat
UCMSC-treated tumor, arrow indicates tumor margin). Scale bars in Panel A and B indicate 500 μm and 100 μm, respectively.
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dance, low immunogenicity [14], lack of CD34 and
CD45 expression, and simplicity of the methods for har-
vest and in vitro expansion [12,24,25]. These properties
of UCMSCs encourage their development as therapeutic
t o o l so ra g e n t sb e c a u s et h e yc a np o t e n t i a l l yb eu s e df o r
allogeneic transplantation.
Conclusions
In in vitro studies, co-culture of rat UCMSCs signifi-
cantly attenuated the proliferation of LLC cells as moni-
tored by MTT assay, thymidine uptake, and direct cell
counts. Rat UCMSCs also markedly reduced LLC colony
size and number. Co-culture of rat UCMSCs caused G0/
G1 arrest of LLC cells. This is evident in the decrease of
cyclin A and CDK2 expression. The in vivo studies
showed that rat UCMSC treatment significantly
decreased tumor weight and the total tumor area. Histo-
logical study revealed that intratracheally or systemically
administered rat UCMSCs homed to tumor areas and
survived for at least 3 weeks without any evidence of
differentiation or adverse effects. Thus the findings
described here suggest that UCMSCs may represent a
new therapeutic modality for the treatment of lung can-
cer and will have important implications for patients
with lung cancer and other types of cancer.
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positive cells (panels A and B) as described in Materials and Methods. The average TUNEL positive area(C) were determined by analyzing ten
tumor areas in each treatment group and expressed as fold change compared to PBS-treated controls.
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